Current and future developments in travelers' diarrhea therapy

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 3, 2006, Pages 417-427

  Koo, Hoonmo L ^a   DuPont, Herbert L ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ST LUKE'S EPISCOPAL HEALTH SYSTEM   (United States)

Author keywords

Azithromycin; Bismuth subsalicylate; Fluoroquinolones; Loperamide; Postinfectious irritable bowel syndrome; Probiotics; Rifaximin; Travelers' diarrhea

Indexed keywords

ACETORPHAN; ADSORBENT; ATROPINE; ATTAPULGITE; AZITHROMYCIN; BACTERIAL ANTIGEN; BISMUTH SALICYLATE; CHOLERA TOXIN B SUBUNIT; CIPROFLOXACIN; COTRIMOXAZOLE; CROFELEMER; DIPHENOXYLATE; ESCHERICHIA COLI ENTEROTOXIN; GATIFLOXACIN; KAOLIN; LEVOFLOXACIN; LOPERAMIDE; MOXIFLOXACIN; ORAL REHYDRATION SOLUTION; PECTIN; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT PROBIOTIC AGENT; RIFAXIMIN; SHIGELLA VACCINE; UNCLASSIFIED DRUG; ZALDARIDE MALEATE;

ANTIBIOTIC RESISTANCE; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; COLIFORM BACTERIUM; DEVELOPING COUNTRY; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DRUG ABSORPTION; DRUG COST; DRUG SAFETY; FECES COLOR; FLUID INTAKE; FOOD SAFETY; GOVERNMENT REGULATION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOPROPHYLAXIS; INFECTION RISK; INTESTINE FLORA; IRRITABLE COLON; ORAL REHYDRATION THERAPY; PATHOGENESIS; REVIEW; SALT INTAKE; TONGUE DISEASE; TRAVELLER DIARRHEA; TROPICS; URINE RETENTION; VACCINATION; VERNER MORRISON SYNDROME; VISUAL IMPAIRMENT; XEROSTOMIA;

BISMUTH; DIARRHEA; FLUID THERAPY; HUMANS; ORGANOMETALLIC COMPOUNDS; PROBIOTICS; RIFAMYCINS; RISK FACTORS; SALICYLATES; TRAVEL;

EID: 33745192287     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.3.417     Document Type: Review

References (104)

1. DuPont AW, DuPont HL. Travelers' diarrhea: modern concepts and new developments. Curr. Treat. Options Gastroenterol. 9(1), 13-21 (2006).
2. DuPont H. Travelers' diarrhea: antimicrobial therapy and chemoprevention. Nature Clin. Pract. Gastroenterol. Hepatol. 2, 191-198 (2005).
3. Al-Abri SS, Beeching NJ, Nye FJ. Traveller's diarrhoea. Lancet Infect. Dis. 5(6), 349-360 (2005).
4. Adachi JA, Jiang ZD, Mathewson JJ et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin. Infect. Dis. 32(12), 1706-1709 (2001).
5. Jiang ZD, Lowe B, Verenkar MP et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J. Infect. Dis. 185(4), 497-502 (2002).
6. Echeverria P, Sack RB, Blacklow NR, Bodhidatta P, Rowe B, McFarland A. Prophylactic doxycycline for travelers' diarrhea in Thailand. Further supportive evidence of Aeromonas bydrophila as an enteric pathogen. Am. J. Epidemiol. 120(6), 912-921 (1984).
7. Sriratanaban A, Reinprayoon S. Vibrio parahaemolyticus: a major cause of travelers' diarrhea in Bangkok. Am. J. Trop. Med. Hyg. 31(1), 128-130 (1982).
8. Ko G, Garcia C, Jiang ZD et al. Noroviruses as a cause of traveler's diarrhea among students from the United States visiting Mexico. J. Clin. Microbiol. 43(12), 6126-6129 (2005).
9. Helms M, Simonsen J, Olsen KE, Molbak K. Adverse health events associated with antimicrobial drug resistance in Campylobacter species: a registry-based cohort study. J. Infect. Dis. 191(7), 1050-1055 (2005).
10. Nelson JM, Smith KE, Vugia DJ et al. Prolonged diarrhea due to ciprofloxacin-resistant Campylobacter infection. J. Infect. Dis. 190(6), 1150-1157 (2004).
11. Hoge CW, Gambel JM, Srijan A, Pitarangsi C, Echeverria P. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin. Infect. Dis. 26(2), 341-345 (1998).
12. DuPont HL, Haynes GA, Pickering LK, Tjoa W, Sullivan P, Olarte J. Diarrhea of travelers to Mexico. Relative susceptibility of United States and Latin American students attending a Mexican University. Am. J. Epidemiol. 105 (1), 37-41 (1977).
13. Steffen R. Epidemiologic studies of travelers' diarrhea, severe gastrointestinal infections, and cholera. Rev. Infect. Dis. 8(Suppl. 2), S122-S130 (1986).
14. Steffen R, van der Linde F, Gyr K, Schar M. Epidemiology of diarrhea in travelers. JAMA 249(9), 1176-1180 (1983).
15. Glass RI, Holmgren J, Haley CE et al. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am. J. Epidemiol. 121(6), 791-796 (1985).
16. Huang P, Farkas T, Zhong W et al. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J. Virol. 79(11), 6714-6722 (2005).
17. Hutson AM, Airaud F, LePendu J, Estes MK, Atmar RL. Norwalk virus infection associates with secretor status genotyped from sera. J. Med. Virol. 77(1), 116-120 (2005).
18. Hutson AM, Atmar RL, Graham DY, Estes MK. Norwalk virus infection and disease is associated with ABO histo-blood group type. J. Infect. Dis. 185(9), 1335-1337 (2002).
19. Greenberg DE, Jiang ZD, Steffen R, Verenker MP, DuPont HL. Markers of inflammation in bacterial diarrhea among travelers, with a focus on enteroaggregative Escherichia coli pathogenicity. J. Infect. Dis. 185(7), 944-949 (2002).
20. Jiang ZD, Okhuysen PC, Guo DC et al. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J. Infect. Dis. 188(4), 506-511 (2003).
21. Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for Campylobacter gastroenteritis: case-control study. Br. Med. J. 312(7028), 414-415 (1996).
22. Cash RA, Music SI, Libonati JP, Snyder MJ, Wenzel RP, Hornick RB. Response of man to infection with Vibrio cholerae. I. Clinical, serologic, and bacteriologic responses to a known inoculum. J. Infect. Dis. 129(1), 45-52 (1974).
23. DuPont HL, Formal SB, Hornick RB et al. Pathogenesis of Escherichia coli diarrhea. N. Engl. J. Med. 285(1), 1-9 (1971).
24. DuPont HL, Jiang ZD, Okhuysen PC et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann. Intern. Med. 142(10), 805-812 (2005).
25. Ericsson CD, Patterson TF, DuPont HL. Clinical presentation as a guide to therapy for travelers' diarrhea. Am. J. Med. Sci. 294(2), 91-96 (1987).
26. Haberberger RL Jr, Mikhail IA, Burans JP et al. Travelers' diarrhea among United States military personnel during joint American-Egyptian armed forces exercises in Cairo, Egypt. Mil. Med. 156(1), 27-30 (1991).
27. Mattila L. Clinical features and duration of traveler's diarrhea in relation to its etiology. Clin. Infect. Dis. 19(4), 728-734 (1994).
28. von Sonnenburg F, Tornieporth N, Waiyaki P et al. Risk and aetiology of diarrhoea at various tourist destinations. Lancet 356(9224), 133-134 (2000).
29. DuPont HL, Capsuto EG. Persistent diarrhea in travelers. Clin. Infect. Dis. 22(1), 124-128 (1996).
30. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am. J. Gastroenterol. 99(9), 1774-1778 (2004).
31. Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 1β in recently acquired postinfectious irritable bowel syndrome. Gut 52(4), 523-526 (2003).
32. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 125(6), 1651-1659 (2003).
33. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am. J. Gastroenterol. 98(7), 1578-1583 (2003).
34. Ruiz-Palacios GM, DuPont HL. Bacterial overgrowth syndrome after acute nonspecific diarrhoea. Lancet 1(8059), 337-338 (1978).
35. Brunser O, Eidelman S, Klipstein FA. Intestinal morphology of rural Haitians. A comparison between overt tropical sprue and asymptomatic subjects. Gastrology 58(5), 655-668 (1970).
36. Landzberg BR, Connor BA. Persistent diarrhea in the returning traveler: think beyond persistent infection. Scand. J. Gastroenterol. 40(1), 112-114 (2005).
37. Yanai-Kopelman D, Paz A, Rippel D, Potasman I. Inflammatory bowel disease in returning travelers. J. Travel Med. 7(6), 333-335 (2000).
38. Connor BA. Sequelae of traveler's diarrhea: focus on postinfectious irritable bowel syndrome. Clin. Infect. Dis. 41 (Suppl. 8), S577-S586 (2005).
39. DuPont HL, Ericsson CD, Mathewson JJ, de la Cabada FJ, Conrad DA. Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico. JAMA 267(14), 1932-1935 (1992).
40. DuPont HL, Ericsson CD, Mathewson JJ, DuPont MW. Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study. Antimicrob. Agents Chemother. 36(1), 87-91 (1992).
41. DuPont HL, Reves RR, Galindo E, Sullivan PS, Wood LV, Mendiola JG. Treatment of travelers' diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. N. Engl. J. Med. 307(14), 841-844 (1982).
42. Gomi H, Jiang ZD, Adachi JA et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob. Agents Chemother. 45 (1), 212-216 (2001).
43. Ericsson CD, DuPont HL, Mathewson JJ. Single dose ofloxacin plus loperamide compared with single dose or three days of ofloxacin in the treatment of traveler's diarrhea. J. Travel Med. 4(1), 3-7 (1997).
44. Ericsson CD, Johnson PC, DuPont HL, Morgan DR, Bitsura JA, de la Cabada FJ. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial. Ann. Intern. Med. 106(2), 216-220 (1987).
45. Salam I, Katelaris P, Leigh-Smith S, Farthing MJ. Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea. Lancet 344(8936), 1537-1539 (1994).
46. Taylor DN, Sanchez JL, Candler W, Thornton S, McQueen C, Echeverria P. Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. Ann. Intern. Med. 114(9), 731-734 (1991).
47. Kuschner RA, Trofa AF, Thomas RJ et al Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin. Infect. Dis. 21(3), 536-541 (1995).
48. DuPont HL. Antimicrobial-resistant Campylobacter species - a new threat to travelers to Thailand. Clin. Infect. Dis. 21(3), 542-543 (1995).
49. Gaunt PN, Piddock LJ. Ciprofloxacin resistant Campylobacter spp. in humans: an epidemiological and laboratory study. J. Antimicrob. Chemother. 37(4), 747-757 (1996).
50. Nachamkin I, Ung H, Li M. Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA, 1982-2001. Emerg. Infect. Dis. 8(12), 1501-1503 (2002).
51. Smith KE, Besser JM, Hedberg CW et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. N. Engl. J. Med. 340(20), 1525-1532 (1999).
52. Krausse R, Ullmann U. In vitro activities of new fluoroquinolones against Campylobacter jejuni and Campylobacter coli isolates obtained from humans in 1980 to 1982 and 1997 to 2001. Antimicrob. Agents Chemother. 47(9), 2946-2950 (2003).
53. Adachi JA, Ericsson CD, Jiang Z-D et al. Azithromycin is comparable to levofloxacin in the treatment of U.S. travelers with acute diarrhea acquired in Mexico. Clin. Infect. Dis. 37, 1165-1171 (2003).
54. Hoover WW, Gerlach EH, Hoban DJ, Eliopoulos GM, Pfaller MA, Jones RN. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn. Microbiol. Infect. Dis. 16(2), 111-118 (1993).
55. Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob. Agents Chemotber., 44(8), 2205-2206 (2000).
56. DuPont HL, Ericsson CD, Mathewson JJ et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion 59(6), 708-714 (1998).
57. DuPont HL, Jiang ZD, Ericsson CD et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin. Infect. Dis. 33(11), 1807-1815 (2001).
58. Steffen R, Sack DA, Riopel L et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am. J. Gastroenterol. 98(5), 1073-1078 (2003).
59. Taylor D, Bourgeois A, Ericsson C et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am. J. Trop. Med. Hyg. (2006) (In press).
60. Malvisi Stracciari J, Venturini AP, Anfossi P, Marchi E, Stracciari GL. Sensitivity to rifaximin and rifampicin of Mycobacterium tuberculosis isolated from guinea pigs treated orally with rifaximin. Chemioterapia 6(2), 82-84 (1987).
61. Soro O, Pesce A, Raggi M, Debbia EA, Schito GC. Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin. Clin. Microbiol. Infect. 3(1), 147-151 (1997).
62. Portnoy BL, DuPont HL, Pruitt D, Abdo JA, Rodriguez JT. Antidiarrheal agents in the treatment of acute diarrhea in children. JAMA 236(7), 844-846 (1976).
63. Reves R, Bass P, DuPont HL, Sullivan P, Mendiola J. Failure to demonstrate effectiveness of an anticholinergic drug in the symptomatic treatment of acute travelers' diarrhea. J. Clin. Gastroenterol. 5(3), 223-237 (1983).
64. Schiller LR, Santa Ana CA, Morawski SG, Fordtran JS. Mechanism of the antidiarrheal effect of loperamide. Gastroenterology 86(6), 1475-1480 (1984).
65. DuPont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. JAMA 226(13), 1525-1528 (1973).
66. DuPont HL, Sullivan P, Pickering LK, Haynes G, Ackerman PB. Symptomatic treatment of diarrhea with bismuth subsalicylate among students attending a Mexican university. Gastroenterology 730(4 Pt 1), 715-718 (1977).
67. Powell DW, Tapper EJ, Morris SM. Aspirin-stimulated intestinal electrolyte transport in rabbit ileum In vitro. Gastroenterology 76(6), 1429-1437 (1979).
68. DuPont HL, Flores Sanchez J, Ericsson CD et al. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. Am. J. Med. 88(6A), 15S-19S (1990).
69. Johnson PC, Ericsson CD, DuPont HL, Morgan DR, Bitsura JA, Wood LV. Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea. JAMA 255(6), 757-760 (1986).
70. Salazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, Gutierrez M. Racecadotril in the treatment of acute watery diarrhea in children. N. Engl. J. Med. 343(7), 463-467 (2000).
71. DuPont HL, Ericsson CD, Mathewson JJ, Marani S, Knellwolf-Cousin AL, Martinez-Sandoval FG. Zaldaride maleate, an intestinal calmodulin inhibitor, in the therapy of travelers' diarrhea. Gastroenterology 104(3), 709-715 (1993).
72. DiCesare D, DuPont HL, Mathewson JJ et al. A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am. J. Gastroenterol. 97(10), 2585-2588 (2002).
73. Prado D. A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults. Scand. J. Gastroenterol. 37(6), 656-661 (2002).
74. Okhuysen PC, DuPont HL, Ericsson CD et al. Zaldaride maleate (a new calmodulin antagonist) versus loperamide in the treatment of traveler's diarrhea: randomized, placebo-controlled trial. Clin. Infect. Dis. 21(2), 341-344 (1995).
75. Siberschmidt G, Schick MT, Steffen R et al. Treatment of travellers' diarrhoea: zaldaride compared with loperamide and placebo. Eur. J. Gastroenterol. Hepatol. 7, 871-875 (1995).
76. Munoz P, Bouza E, Cuenca-Estrella M et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin. Infect. Dis. 40(11), 1625-1634 (2005).
77. Ericsson CD, DuPont HL, Okhuysen PC et al. Azithromycin (500 mg) plus loperamide effectively treats travelers' diarrhea in Mexico. 9th Conference International Soc Travel Med. Lisbon, Portugal, May 2, Abstract FC01.10 (2005).
78. Petruccelli BE, Murphy GS, Sanchez JL et al. Treatment of traveler's diarrhea with ciprofloxacin and loperamide. J. Infect. Dis. 165(3), 557-560 (1992).
79. Murphy GS, Bodhidatta, L, Echeverria P et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann. Intern. Med. 118(8), 582-586 (1993).
80. Caeiro JP, DuPont HL, Albrecht H, Ericsson CD. Oral rehydration therapy plus loperamide versus loperamide alone in the treatment of traveler's diarrhea. Clin. Infect. Dis. 28(6), 1286-1289 (1999).
81. Kozicki M, Steffen R, Schar M. 'Boil it, cook it, peel it or forget it': does this rule prevent travellers' diarrhoea? Int. J. Epidemiol. 14(1), 169-172 (1985).
82. Bandres JC, Mathewson JJ, DuPont HL. Heat susceptibility of bacterial enteropathogens. Implications for the prevention of travelers' diarrhea. Arch. Intern. Med. 148(10), 2261-2263 (1988).
83. Shlim DR. Looking for evidence that personal hygiene precautions prevent traveler's diarrhea. Clin. Infect. Dis. 41(Suppl. 8), S531-S535 (2005).
84. Adachi JA, Mathewson JJ, Jiang ZD, Ericsson CD, DuPont HL. Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico, and Houston, Texas. Ann. Intern. Med. 136(12), 884-887 (2002).
85. Tjoa WS, DuPont HL, Sullivan P et al. Location of food consumption and travelers' diarrhea. Am. J. Epidemiol. 106(1), 61-66 (1977).
86. Wood LV, Ferguson LE, Hogan P et al. Incidence of bacterial enteropathogens in foods from Mexico. Appl. Environ. Microbial. 46(2), 328-332 (1983).
87. Kean BH, Waters S. The diarrhea of travelers. I. Incidence in travelers returning to the United States from Mexico. AMA Arch. Ind. Health. 18(2), 148-150 (1958).
88. Gorbach S, Edelman R. Travelers' diarrhea: National Institutes of Health Consensus Development Conference. Rev. Infect. Dis. S209-S233 (1986).
89. DuPont HL, Ericsson CD, Johnson PC, Bitsura JA, DuPont MW, de la Cabada FJ. Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate. JAMA 257(10), 1347-1350 (1987).
90. DuPont HL, Sullivan P, Evans DG et al. Prevention of traveler's diarrhea (emporiatric enteritis). Prophylactic administration of subsalicylate bismuth). JAMA 243(3), 237-241 (1980).
91. Steffen R, DuPont HL, Heusser R et al. Prevention of traveler's diarrhea by the tablet form of bismuth subsalicylate. Antimicrob. Agents Chemother. 29(4), 625-627 (1986).
92. Ericsson CD, Feldman S, Pickering LK, Cleary TG. Influence of subsalicylate bismuth on absorption of doxycycline. JAMA 247(16), 2266-2267 (1982).
93. Kollaritsch H, Hoist H, Grobara P, Wiedermann G. [Prevention of traveler's diarrhea with Saccharomyces boulardii. results of a placebo controlled double-blind study]. Fortschr. Med. 111(9), 152-156 (1993).
94. Hilton E, Kolakowski P, Singer C, Smith M. Efficacy of Lactobacillus GG as a diarrheal preventive in travelers. J. Travel Med. 4(1), 41-43 (1997).
95. Paton AW, Morona R, Paton JC. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nature Med. 6(3), 265-270 (2000).
96. Paton AW, Jennings MP, Morona R et al. Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology 128(5), 219-1228 (2005).
97. Johnson PC, Ericsson CD, Morgan DR DuPont HL, Cabada FJ. Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin. Antimicrob. Agents Chemother. 30(5), 671-674 (1986).
98. Taylor DN, McKenzie R, Durbin A et al. Rifaximin, a nonabsorbed oral antibiotic prevents shigellosis after experimental challenge. Clin. Infect. Dis. 42(9), 1283-1288 (2006).
99. Boedeker EC. Vaccines for enterotoxigenic Esherichia coli. current status. Curr. Opin. Gastroenterol. 21(1), 15-19 (2005).
100. Peltola H, Siitonen A, Kyronseppa H et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 338(8778), 1285-1289 (1991).
101. Barry EM, Wang J, Wu T, Davis T, Levine MM. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Vaccine 24(18), 3727-3734 (2005).
102. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano, A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nature Med. 6(12), 1403-1406 (2000).
103. Ashley DV, Walters C, Dockery-Brown C, McNab A, Ashley DE. Interventions to prevent and control food-borne diseases associated with a reduction in traveler's diarrhea in tourists to Jamaica. J. Travel Med. 11(6), 364-367 (2004).
104. Steffen R, Collard F, Tornieporth N et al. Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica. JAMA 281(9), 811-817 (1999).